drugset

drugset / Trial / NCT01943045

Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

NCT01943045 ↗

Phase 2 Completed 81 enrolled NGM Biopharmaceuticals, Inc NGM Biopharmaceuticals Australia Pty Ltd · collab

RandomizedFactorialDouble-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Type 2 Diabetes.

Timeline

Start: 2013-09
Primary completion: 2014-09
Completion: 2014-09

Publications

DePaoli AM, Zhou M, Kaplan DD, Hunt SC, Adams TD, Learned RM, Tian H, Ling L. FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis. Diabetes. 2019 Jun;68(6):1315-1328. doi: 10.2337/db18-1305. Epub 2019 Mar 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aldafermin	Protein / enzyme biologic	—	—

Indications